Value
7.5/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 7.5 |
- ▸Attractively valued
GHRS · Why this verdict
Why GH Research (GHRS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
GH Research shows a favorable 1.82 asymmetry setup with 27% modeled upside, but weak quality fundamentals at a 1.6 score with ongoing cash burn, an overbought technical reading, and an elevated put/call ratio all warrant caution ahead of binary biotech catalysts.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The engine's asymmetry gate cleared at 1.82, well above the 1.5 threshold, with 27.2% modeled upside against 15% downside to the analyst-target-derived take-profit. Engine gate (passed) | The asymmetry ratio should stay above 1.5 or improve further as the stock moves toward its take-profit level. | →Stable |
| CounterIn binary biotech names, a favorable asymmetry ratio can flip sharply on a single clinical or regulatory data readout, invalidating the risk/reward math overnight. | ||
GH Research is cash-burning with negative free cash flow and no identifiable competitive moat, and its quality score of 1.6 sits well below the engine's 4.0 floor. Quality breakdown | Free cash flow should turn less negative or positive, lifting the quality score toward the 4.0 floor. | →Stable |
| CounterClinical-stage biotech companies routinely burn cash pre-commercialization, so a low quality score here may simply reflect the sector's business model rather than firm-specific weakness. | ||
The stock is technically overbought with RSI at 74, even as it trades above its 200-day moving average. Momentum breakdown | RSI should cool into a more neutral 40-60 range without a disorderly price decline. | ↑Improving |
| CounterSustained overbought readings in strong-momentum names can persist for extended periods without triggering a reversal, especially heading into a binary catalyst. | ||
The options market shows an elevated put/call ratio of 2.20, which the engine flags as a key risk signaling defensive positioning ahead of the next catalyst. Key risks | The put/call ratio should normalize toward 1.0 or lower as hedging pressure eases. | ↓Deteriorating |
| CounterA high put/call ratio in biotech is often just pre-earnings or pre-data hedging rather than a directional bearish signal, and can persist right up to the catalyst date. | ||
The engine's asymmetry gate cleared at 1.82, well above the 1.5 threshold, with 27.2% modeled upside against 15% downside to the analyst-target-derived take-profit.
→StableEngine gate (passed)
- Expectation
- The asymmetry ratio should stay above 1.5 or improve further as the stock moves toward its take-profit level.
CounterIn binary biotech names, a favorable asymmetry ratio can flip sharply on a single clinical or regulatory data readout, invalidating the risk/reward math overnight.
GH Research is cash-burning with negative free cash flow and no identifiable competitive moat, and its quality score of 1.6 sits well below the engine's 4.0 floor.
→StableQuality breakdown
- Expectation
- Free cash flow should turn less negative or positive, lifting the quality score toward the 4.0 floor.
CounterClinical-stage biotech companies routinely burn cash pre-commercialization, so a low quality score here may simply reflect the sector's business model rather than firm-specific weakness.
The stock is technically overbought with RSI at 74, even as it trades above its 200-day moving average.
↑ImprovingMomentum breakdown
- Expectation
- RSI should cool into a more neutral 40-60 range without a disorderly price decline.
CounterSustained overbought readings in strong-momentum names can persist for extended periods without triggering a reversal, especially heading into a binary catalyst.
The options market shows an elevated put/call ratio of 2.20, which the engine flags as a key risk signaling defensive positioning ahead of the next catalyst.
↓DeterioratingKey risks
- Expectation
- The put/call ratio should normalize toward 1.0 or lower as hedging pressure eases.
CounterA high put/call ratio in biotech is often just pre-earnings or pre-data hedging rather than a directional bearish signal, and can persist right up to the catalyst date.
Per-dimension breakdown
Quality
1.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.8 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.9 |
| Price target | 9.2 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 40%
Insider
5.0/10data confidence 50%Peer rank
6.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 6.9 |
| growth rank | 5.0 |
- ▸Conservative debt levels
Technical
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.8 |
| support resistance | 4.1 |
| 52w position | 8.2 |
| gap | 6.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.4 |
| days to cover | 3.3 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 5.8 |
| debt equity | 10.0 |
- ▸Elevated put/call: 7.46
- ▸High IV: 80%
Catalyst
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 5.6 |
| news activity | 6.0 |
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:5.7>=5.5
- ASYMMETRY:1.6>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
1.56
Upside
+21.6%
Downside
13.9%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($2.0B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Sentiment at 7.8 and asymmetric R:R of 1.56.
The strongest dimensions are Sentiment at 7.8, Value at 7.5, and Peer rank at 6.6; the weakest are Quality at 1.6, Risk (lower is worse) at 3.6, and Insider at 5.0. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 1.56 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Asymmetric Risk Reward Setup
Trip ifAsymmetry ratio falls below 1.5, down from the current 1.82, failing the gate it currently clears.
- P2Cash Burning Quality Floor Breach
Trip ifFree cash flow stays below $0 for 2 more consecutive quarters, deepening the current cash burn.
- P3Overbought Technical Condition
Trip ifRSI falls below 30 within the next month, reversing sharply from the current overbought 74.
- P4Elevated Put Call Hedging Signal
Trip ifPut/call ratio stays above 2.0 for more than 2 consecutive reporting periods, showing hedging pressure isn't easing.